Raymond James Financial Services Advisors Inc. Sells 5,411 Shares of Hologic, Inc. (NASDAQ:HOLX)

Raymond James Financial Services Advisors Inc. decreased its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 35.9% during the fourth quarter, HoldingsChannel reports. The firm owned 9,682 shares of the medical equipment provider’s stock after selling 5,411 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Hologic were worth $692,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of HOLX. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in shares of Hologic by 5.1% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 33,448 shares of the medical equipment provider’s stock valued at $2,569,000 after purchasing an additional 1,631 shares in the last quarter. LSV Asset Management boosted its stake in shares of Hologic by 307.5% during the 1st quarter. LSV Asset Management now owns 37,900 shares of the medical equipment provider’s stock valued at $2,911,000 after purchasing an additional 28,600 shares in the last quarter. Raymond James Trust N.A. boosted its stake in shares of Hologic by 7.4% during the 1st quarter. Raymond James Trust N.A. now owns 6,875 shares of the medical equipment provider’s stock valued at $528,000 after purchasing an additional 476 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Hologic by 4.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,305,399 shares of the medical equipment provider’s stock valued at $177,098,000 after acquiring an additional 106,315 shares during the period. Finally, Aviva PLC lifted its position in Hologic by 0.7% during the 1st quarter. Aviva PLC now owns 75,543 shares of the medical equipment provider’s stock valued at $5,803,000 after acquiring an additional 513 shares during the period. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on HOLX shares. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the company from $80.00 to $95.00 in a research report on Wednesday, April 3rd. Raymond James lifted their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a research report on Friday, February 2nd. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Friday, March 8th. Finally, Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Six equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, Hologic currently has a consensus rating of “Hold” and an average target price of $87.00.

Insider Buying and Selling at Hologic

In other news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now owns 48,611 shares in the company, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the completion of the sale, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at $7,793,700. The disclosure for this sale can be found here. Insiders sold a total of 32,846 shares of company stock worth $2,473,443 in the last three months. 1.75% of the stock is currently owned by company insiders.

Hologic Stock Performance

Shares of HOLX stock opened at $74.92 on Thursday. The company has a 50 day moving average price of $75.68 and a 200-day moving average price of $72.48. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $87.88. The firm has a market capitalization of $17.59 billion, a PE ratio of 35.51, a P/E/G ratio of 2.62 and a beta of 1.00. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $989.32 million. During the same period in the previous year, the business posted $1.07 earnings per share. The business’s revenue for the quarter was down 5.7% on a year-over-year basis. As a group, equities research analysts expect that Hologic, Inc. will post 4.02 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.